Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vor Biopharma Inc (VOR)
Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,188
  • Shares Outstanding, K 67,806
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,094 K
  • 60-Month Beta -0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VOR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings -0.49 on 11/07/23
  • Next Earnings Date 11/09/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Biomedical

    Indices Russell 2000

Options Overview Details

View History
  • Implied Volatility 157.83% ( -0.15%)
  • Historical Volatility 91.23%
  • IV Percentile 94%
  • IV Rank 42.38%
  • IV High 317.32% on 10/10/23
  • IV Low 40.55% on 07/20/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 141
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 795
  • Open Int (30-Day) 737

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.49
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.52
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +7.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6200 +32.72%
on 11/21/23
2.1800 -1.38%
on 12/04/23
+0.2700 (+14.36%)
since 11/03/23
3-Month
1.6200 +32.72%
on 11/21/23
2.7900 -22.94%
on 09/05/23
-0.5200 (-19.48%)
since 09/01/23
52-Week
1.6200 +32.72%
on 11/21/23
7.5700 -71.60%
on 12/13/22
-2.8000 (-56.57%)
since 12/02/22

Most Recent Stories

More News
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.25 (-1.38%)
PRTC.LN : 149.800 (-0.66%)
BIIB : 232.85 (-0.76%)
KRTX : 197.57 (+0.53%)
VOR : 2.1500 (+11.98%)
AKLI : 0.4760 (-2.86%)
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

VOR : 2.1500 (+11.98%)
PureTech Provides End of Year Report on Key Progress

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today...

PRTC : 19.25 (-1.38%)
PRTC.LN : 149.800 (-0.66%)
KRTX : 197.57 (+0.53%)
GLS : 0.1586 (+0.38%)
VOR : 2.1500 (+11.98%)
AKLI : 0.4760 (-2.86%)
BIIB : 232.85 (-0.76%)
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

VOR : 2.1500 (+11.98%)
PureTech Health plc – Half-Year Report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. The following information will be filed...

PRTC : 19.25 (-1.38%)
PRTC.LN : 149.800 (-0.66%)
AKLI : 0.4760 (-2.86%)
GLS : 0.1586 (+0.38%)
DNAA : 14.07 (+47.02%)
RBLX : 41.23 (+1.93%)
CPSR : 7.36 (+9.85%)
KRTX : 197.57 (+0.53%)
VOR : 2.1500 (+11.98%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 2.1500 (+11.98%)
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for...

VOR : 2.1500 (+11.98%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 2.1500 (+11.98%)
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant...

VOR : 2.1500 (+11.98%)
Vor Bio Announces Retirement of Chief Medical Officer

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that...

VOR : 2.1500 (+11.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.4900
2nd Resistance Point 2.3400
1st Resistance Point 2.2400
Last Price 2.1500
1st Support Level 1.9900
2nd Support Level 1.8400
3rd Support Level 1.7400

See More

52-Week High 7.5700
Fibonacci 61.8% 5.3000
Fibonacci 50% 4.6000
Fibonacci 38.2% 3.8900
Last Price 2.1500
52-Week Low 1.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar